Merck anticipates that starting in 2026, their cancer treatment drug Keytruda will be subject to the pricing process set by the Inflation Reduction Act (IRA).
Merck is preparing for a big change in 2028 when the sales growth of its popular cancer drug, Keytruda, is expected to slow down significantly. This change is due to several reasons, including competition from other medications.